Metropolitan General Hospital
- Address
- lock Available on a paid plan
Cardiovascular Research
The Cardiology department at Metropolitan General Hospital is evaluating new strategies to lower the risk of ischemic stroke in patients with atrial fibrillation who cannot take oral anticoagulants.
- Stroke risk reduction
- Alternative to oral anticoagulation
- Safety and efficacy of novel anticoagulant
This work aims to improve outcomes for high‑risk heart rhythm patients and could expand treatment options beyond traditional blood thinners.
Oncology Research
Researchers are testing a combination of capivasertib and docetaxel in men with metastatic castration‑resistant prostate cancer to see if it extends overall survival and delays disease progression.
- Targeted kinase inhibition
- Chemotherapy synergy
- Survival benefit assessment
The trial reflects Metropolitan General Hospital’s commitment to advancing cancer therapy and offering hope to patients with advanced prostate disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Anthos Therapeutics Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Metropolitan General Hospital
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Capivasertib Plus Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Study | AstraZeneca AB | Phase III | Not Recruiting | Jul 2022 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abelacimab | 1 | Unknown | 2023-10-31 | 2023-10-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.